louisakewell, Author at European Medical Journal - Page 66 of 153

Learning from Actual Practice: Registry Studies Promote Quality Treatment

Geneva, 1 June 2016 – What kinds of prosthetic joints are frequently used in a specific country? How durable are they and how often do they cause…

Prevention Is the Key: EFORT Calls for Better Frameworks to Keep People Moving and Active

Geneva, 1 June 2016 – Keeping people active, mobile and pain-free throughout life, and the contribution orthopaedics can make in an ageing society are…

Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis from Two Phase III Studies for Anamorelin in Cachectic Patients with Non-Small Cell Lung Cancer (NSCLC)

Lugano, Switzerland, June 1, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that it will present…

Janssen’s IMBRUVICA®▼(Ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia

Beerse/Belgium, 31 May, 2016 – Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved IMBRUVICA®…

European Commission Approves TREVICTA®(Paliperidone Palmitate a 3-Monthly Injection), for Maintenance Treatment of Schizophrenia

BEERSE, BELGIUM, 31st May 2016 – Janssen-Cilag International NV announced today that the European Commission (EC) has approved the use of TREVICTA®…

Children’s Digestive Health Across Europe in Crisis

Brussels, 31 May, 2016: A report investigating the current state of digestive health in children has revealed alarming trends in disease incidence and…

Introducing EMJ Hepatology 4.1

United Kingdom, May 31, 2016: Welcome to the latest edition of EMJ Hepatology, which provides a collection of articles on the latest hepatology research…

EMJ

KEYNOTE-010: Pembrolizumab versus docetaxel in advanced PD-L1-positive NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…

EMJ

ASCEND-2 and ASCEND-3 trials: Ceritinib in ALK-rearranged NSCLC with brain metastases

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…

EMJ

Immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…